Addition of drug/s to a chemotherapy regimen for metastatic breast cancer
- 10 November 2010
- journal article
- research article
- Published by Wiley in Emergencias
- Vol. 2021 (5), CD003368
- https://doi.org/10.1002/14651858.cd003368.pub3
Abstract
The addition of a chemotherapy drug or drugs to an established regimen is one method used to increase the dose and intensity of treatment for metastatic breast cancer. To assess the effects of adding one or more chemotherapy drugs to an established regimen in women with metastatic breast cancer. We searched the Cochrane Breast Cancer Group's Specialised Register (to August 2009) using the codes for "advanced breast cancer" and "chemotherapy". This review is an update of the original Cochrane Review (Issue 3, 2006). Randomised trials with a first line regimen of at least two chemotherapy drugs compared to the same regimen plus the addition of one or more chemotherapy drugs in women with metastatic breast cancer. Two authors extracted data independently from published trials. We derived hazard ratios (HR) from time-to-event outcomes where possible, and used a fixed-effect model for meta-analysis. We analysed response rates as dichotomous variables and extracted toxicity data where available. We identified 17 trials reporting on 22 treatment comparisons (2674 patients randomised). Fifteen trials (20 treatment comparisons) reported results for tumour response and 11 trials (14 treatment comparisons) published time-to-event data for overall survival. There were 1532 deaths in 2116 women randomised to trials of the addition of a drug to the regimen and control (the regimen alone). There was no detectable difference in overall survival between these patients, with an overall HR of 0.96 (95% confidence interval (CI) 0.87 to 1.07, P = 0.47) and no significant heterogeneity. We found no difference in time to progression between these regimens, with an overall HR of 0.93 (95% CI 0.81 to 1.07, P = 0.31) and no significant heterogeneity. Addition of a drug to the regimen was favourably associated with overall tumour response rates (odds ratio 1.21, 95% CI 1.01 to 1.44, P = 0.04) although we observed significant heterogeneity for this outcome across the trials. Where measured, acute toxicities such as alopecia, nausea and vomiting and leucopenia were more common with the addition of a drug. The addition of one or more drugs to the regimen shows a statistically significant advantage for tumour response in women with metastatic breast cancer but the results suggest no difference in survival time or time to progression. The positive effect on tumour response was also associated with increased toxicity.Keywords
This publication has 46 references indexed in Scilit:
- Dofequidar Fumarate (MS-209) in Combination With Cyclophosphamide, Doxorubicin, and Fluorouracil for Patients With Advanced or Recurrent Breast CancerJournal of Clinical Oncology, 2007
- Single agent versus combination chemotherapy for metastatic breast cancerPublished by Wiley ,2005
- Chemotherapy: What Progress in the Last 5 Years?Journal of Clinical Oncology, 2005
- Antitumour antibiotic containing regimens for metastatic breast cancerEmergencias, 2004
- Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trialEuropean Journal of Cancer, 1992
- Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancerCancer, 1989
- An evaluation of the effect of vincristine added to cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone in advanced breast cancerBreast Cancer Research and Treatment, 1985
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985
- Randomized trial of 3 different regimens of combination chemotherapy in patients receiving simultaneously a hormonal treatment for advanced breast cancerEuropean Journal of Cancer and Clinical Oncology, 1983
- Adriamycin combinations in advanced breast cancer:A southwest oncology group studyCancer, 1982